{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-22-000021","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.190452+00:00","generated_at":"2026-06-25T23:39:27.640186+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Prothena Q1 net loss $36.3M; PRX012 gets Fast Track, Phase 1 started","bullets":["Net loss of $36.3M ($0.78 per share) vs $36.7M loss ($0.91) in Q1 2021; revenue $1.2M.","Cash and restricted cash $544.3M at quarter end; no debt; net cash used in ops/investing $37.4M.","PRX012 initiated Phase 1 SAD study, received FDA Fast Track for Alzheimer's disease.","R&D expense $27.3M (up 29% YoY) driven by birtamimab, PRX012, PRX005 programs.","FY 2022 guidance: net cash outflow $120-132M, net loss $154-170M, year-end cash ~$454M."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-22-000021","json":"https://secwatch.observer/filing/0001559053-22-000021.json","markdown":"https://secwatch.observer/filing/0001559053-22-000021.md","text":"https://secwatch.observer/filing/0001559053-22-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905322000021/0001559053-22-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905322000021/prta-20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:39:27.640186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}